<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210090</url>
  </required_header>
  <id_info>
    <org_study_id>HSCT-CMV-2015-01</org_study_id>
    <nct_id>NCT03210090</nct_id>
  </id_info>
  <brief_title>Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients</brief_title>
  <acronym>CYTHEMAT</acronym>
  <official_title>Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Donor and recipient CMV-serostatus is one of the risk factor for CMV infection in solid organ
      transplantation. Recipients with IgG positive anti-CMV are classified as low-risk patients
      since it is considered that patients also have specific cellular immunity against CMV.
      However, investigators group has published that around 25% of solid organ transplant
      candidates lack CMV-specific CD8+ T-cell response (&quot;humoral/cellular mismatch&quot;) and they are
      at a higher risk of CMV replication after transplantation. The main goal of this study is to
      analyze the impact of the humoral/cellular mismatch in hematopoietic stem cell
      transplantation (HSCT) CMV-seropositive donors on the CMV reactivation after HSCT in
      CMVseropositive recipients. Investigators will study not only the incidence of CMV
      reactivation but also the severity (duration and peak viral load), CMV disease and survival.
      CMV-seropositive patients who receive a HSCT (bone marrow or peripheral blood) from related
      donors will be consecutively recruited from Reina Sofía Hospital (Córdoba) and Marqués de
      Valdecilla Hospital (Santander).

      Patients will be monitored during 12 months after HSCT. CMV-specific CD8+ T-cell response
      will be determined in their donors, using QuantiFERON-CMV assay, to know the frequency of
      humoral/cellular mismatch. Innate and adaptive immune reconstitution will be assessed by flow
      cytometry and experimental QuantiFERON Monitor assay. CMV-specific CD8+ T-cell reconstitution
      will be determined using QuantiFERON-CMV assay.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the incidence and severity of CMV reactivation in CMV-seropositive patients whose stem cells come from CMV seropositive donors lacking CMV-specific CD8+ T-Cell response [D+(T-)/R+] in comparison with D+(T+)/R+ and D-/R+ patients</measure>
    <time_frame>During the 6 months after transplantation</time_frame>
    <description>To determine the incidence and severity of CMV reactivation in CMV-seropositive patients whose stem cells come from CMV seropositive donors lacking CMV-specific CD8+ T-Cell response [D+(T-)/R+] in comparison with D+(T+)/R+ and D-/R+ patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the frequency of CMV-seropositive stem cells donors lacking CMV-specific CD8+ T-Cell response [D+(T-)]</measure>
    <time_frame>3 years</time_frame>
    <description>To analyze the frequency of CMV-seropositive stem cells donors lacking CMV-specific CD8+ T-Cell response [D+(T-)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Innate and adaptive immune reconstitution: Units (percentage and absolute number)</measure>
    <time_frame>3 years</time_frame>
    <description>To analyze the differences in the innate, adaptive as well as CMV-specific immune reconstitution between D+(T-)/R+ vs D-/R+ and D+(T+)/R+ patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of CMV disease as well as the type and severity of the disease in D+(T-)/R+ vs D-/R+ and D+(T+)/R+ patients</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the incidence of CMV disease as well as the type and severity of the disease in D+(T-)/R+ vs D-/R+ and D+(T+)/R+ patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV-specific immune reconstitution: Units (Percentage respect to CD8+ T cells) and interferon-gamma production (IU/mL).</measure>
    <time_frame>3 years</time_frame>
    <description>To test the differences in mortality/survival between the three groups</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <condition>HSCT</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CMV-seropositive patients who receive a HSCT (bone marrow or peripheral blood) from related
        donors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CMV Seropositive patients who receive a HSCT (Bone marrow or peripheral) blood from
             related donors

          2. &gt;14 years old

          3. signed Inform consent form

        Exclusion Criteria:

        1. HIV, HCV, HBV Infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sara Cantisan, PhD</last_name>
    <email>sacanti@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Clavijo</last_name>
    <email>carmen.clavijo@imibic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Gonzalez</last_name>
    </contact>
    <investigator>
      <last_name>Claudia Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosìtal Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Cantisan, PhD</last_name>
      <email>sacanti@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Clavijo</last_name>
      <email>carmen.clavijo@imibic.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sara Cantisan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Martin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cells transplantation</keyword>
  <keyword>Cytomegalovirus infection</keyword>
  <keyword>CMV-Specific Immune response</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Humoral/Cellular mismatch</keyword>
  <keyword>Interferon-gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

